Volition presents lung cancer risk stratification abstract

VolitionRx Limited announced the presentation of an abstract detailing risk stratification in lung cancer at the European Lung Cancer Conference. This presentation highlights the company's ongoing work in epigenetics and its potential applications in oncology diagnostics. The abstract likely showcases data supporting Volition's technology for identifying patients at different risk levels for lung cancer, which could lead to more personalized and effective treatment strategies. This scientific advancement underscores the company's commitment to improving cancer detection and management.